ALERTS, HOT STOCKS & CHARTS

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Jade Power Trust's Annual Meeting Highlights Jade Power Trust (TSXV: JPWR.H) recently concluded its Annual and Special Meeting of unitholders, where significant decisions were made to shape the future of the Trust. The meeting, organized with great attention and resources, took place with a focus on transparency and community engagement. Re-election of Board Members...

Vesper Bio Reports Positive Results from Phase I Study Vesper Bio ApS, a biotech company in the clinical stage known for its advancements in sortilin receptor biology, has made significant strides with its lead candidate, VES001. This groundbreaking compound is emerging as a potentially disease-modifying treatment for patients diagnosed with frontotemporal dementia (FTD),...

Texas Pacific Land Trust Reaches New Heights In a significant display of market strength, Texas Pacific Land Trust (NYSE: TPL) stock has soared to an extraordinary all-time high of $996.82. This remarkable feat highlights a period of impressive growth for the company, as its stock has demonstrated a stunning 63.04% increase over the past year. Investors are exhibiting...

Headwall Photonics scored a major win back in 2024, announcing a strategic partnership with NV5 that aimed to shake up the hyperspectral imaging landscape. The deal wasn’t just about another tech tie-up; it was about embedding NV5's renowned ENVI software into Headwall's offerings, which could change how users handle geospatial data. ENVI Software Integration: What’s...

DZS Inc. Completes Strategic Asset Sale DZS Inc. (OTC: DZSI), known for its advanced network edge, connectivity, and cloud edge software solutions, has successfully completed the sale of its service assurance and WiFi management software portfolio to AXON Networks. This transaction includes key products such as Expresse, CloudCheck, and TruSpeed, along with their...